Product Developments, Partnerships and Validated Clinical Trials Help Diversify Today's Treatments - Research Report on Varian,

    Product Developments, Partnerships and Validated Clinical Trials Help
 Diversify Today's Treatments - Research Report on Varian, Align Technology,
                Volcano, Wright Medical Group, and Cyberonics

  PR Newswire

  NEW YORK, June 6, 2013

NEW YORK, June 6, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom

Today, Wall Street Reports announced new research reports highlighting Varian
Medical Systems Inc. (NYSE: VAR), Align Technology Inc. (NASDAQ: ALGN),
Volcano Corporation (NASDAQ: VOLC), Wright Medical Group Inc. (NASDAQ: WMGI),
and Cyberonics Inc. (NASDAQ: CYBX). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Varian Medical Systems Inc. Research Report

On May 22, 2013, Varian Medical Systems Inc. (Varian Medical) announced that
it received 510 (k) clearance from the U.S. Food and Drug Administration (FDA)
for Varian's diagnostic X-ray image processing workstation that combines
radiography/fluoroscopy (RF) and digital radiography (DR) capabilities on one
platform. "Nexus is Varian's 6th generation image processing platform," said
Carl LaCasce, Vice President and General Manager for Varian's Imaging Products
business. "It's an updated platform designed to provide our customers with a
universal system that addresses both dynamic and static imaging modalities, as
well as CCD camera based fluoroscopy." The Nexus system enables an operator to
acquire, display, process, transmit, export, or print high resolution X-ray
images. "Varian views its Nexus product as a cost effective, reliable solution
to support a wide range of our customers' requirements," concluded LaCasce.
The Full Research Report on Varian Medical Systems Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at [ ]


Align Technology Inc. Research Report

On June 3, 2013, Align Technology Inc. (Align Technology) and Henry Schein
Dental, the US dental business of Henry Schein, Inc., jointly announced the
introduction of Realine, an entry level, five-stage clear aligner product
designed for very minor crowding and spacing issues that general practitioner
(GP) dentists see in their practices every day. "This is Align's first
exclusive distribution partnership in North America for a clear aligner
product," said Greg Morrow, Align Technology Vice President and General
Manager for Invisalign. "Henry Schein Dental provides the reach, scalability,
and strong long term relationships with GP dentists to help Align reach an
untapped market of more than 80,000 dentists with Realine, while still
allowing us to maintain our primary focus on Invisalign providers and
comprehensive orthodontic treatment through Invisalign." Realine will be
available in the US by mid-June 2013 exclusively through Henry Schein Dental,
the world's largest provider of healthcare products and services to
office-based dental practitioners. The Full Research Report on Align
Technology Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at [ ]


Volcano Corporation Research Report

On May 23, 2013, Volcano Corporation (Volcano) announced its preliminary
results from the Adenosine Vasodilator Independent Stenosis Evaluation
(ADVISE) II trial during the clinical trial session at EuroPCR 2013. "An
important step in the validation of any new technology is to identify a
hypothesis based on observations, and to then prospectively test the
hypothesis in a large number of centers to see if the observations translate
to real-world practice," commented Javier Escaned, MD, PhD, Interventional
Cardiologist at Hospital Clínico San Carlos, Madrid, Spain. "The ADVISE II
study is the first prospective test of the true iFR algorithm that is analyzed
through an independent physiology core lab (Cardialysis, Rotterdam,
Netherlands). These preliminary results show that the prior observations can
be replicated prospectively, and that a Hybrid iFR/FFR approach can provide a
greater than 90% agreement with FFR while saving the use of hyperemic agent in
more than half of patients." The Full Research Report on Volcano Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at [ ]


Wright Medical Group Inc. Research Report

On May 14, 2013, Wright Medical Group Inc. (Wright Medical Group) announced
that its shareholders have approved a proposal to increase the size of the
Company's Board to include ten directors. Douglas G. Watson has been elected
as Wright Medical's tenth Director, with immediate effect. Mr. Watson
currently serves as Chairman of the Board of OraSure Technologies, Inc., as a
Lead Director of Dendreon Corporation, and a Director of Delcath Systems, Inc.
"We are delighted to have someone with Doug's proven leadership skills and
extensive operational expertise join our board," said David Stevens, Chairman
of the Board of Wright Medical. "As a past director of BioMimetic
Therapeutics, Doug brings to our Board of Directors an institutional knowledge
of BioMimetic's products and operations that will be of great value as the
company's management team continues to execute its transformational plan, as
well as our strategy of building a world-class biologics platform and
accelerating growth in our foot and ankle business." The Full Research Report
on Wright Medical Group Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at [ ]


Cyberonics Inc. Research Report

On May 28, 2013, Cyberonics, Inc. (Cyberonics) announced the receipt of a
letter from the Centers of Medicare and Medicaid Services (CMS) declining the
Company's request to reconsider the 2007 National Coverage Determination for
the treatment-resistant depression indication. "Cyberonics is very
disappointed in the position taken by CMS that the new evidence accumulated
over the past five years and recently published in four peer-reviewed journals
does not support reconsideration of the non-coverage decision. We believe the
total body of evidence that began appearing in the scientific literature in
1998 presents compelling rationale for access to VNS Therapy in a very ill
subpopulation of Medicare beneficiaries," said Dan Moore, Cyberonics'
President and Chief Executive Officer. "The company plans to work with other
interested parties to continue to pursue access to this important therapeutic
option for patients who could benefit from VNS Therapy, including carefully
evaluating all options for appealing this decision." The Company will provide
additional information at its financial results conference call on June 5,
2013. The Full Research Report on Cyberonics Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at [ ]



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at .
5.For any urgent concerns or inquires , please contact us at .
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

Contact: Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.